BioScrip Inc. (NASDAQ:BIOS)’s share price rose 3% during trading on Tuesday . The stock traded as high as $2.77 and last traded at $2.73, with a volume of 473,162 shares changing hands. The stock had previously closed at $2.65.

Separately, Zacks Investment Research upgraded BioScrip from a “hold” rating to a “buy” rating and set a $3.00 price target for the company in a report on Monday, July 11th.

The firm’s 50-day moving average is $2.62 and its 200 day moving average is $2.37. The company’s market capitalization is $308.61 million.

BioScrip (NASDAQ:BIOS) last released its earnings results on Monday, August 8th. The company reported ($0.14) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by $0.05. The firm earned $232.50 million during the quarter, compared to analysts’ expectations of $229.58 million. The business’s quarterly revenue was down 11.4% on a year-over-year basis. Analysts anticipate that BioScrip Inc. will post ($0.22) EPS for the current fiscal year.

In other BioScrip news, Director David W. Golding acquired 12,500 shares of the business’s stock in a transaction on Friday, June 17th. The shares were bought at an average price of $2.48 per share, with a total value of $31,000.00. Following the transaction, the director now directly owns 42,500 shares of the company’s stock, valued at approximately $105,400. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Coliseum Capital Management, L acquired 4,200,000 shares of the business’s stock in a transaction on Wednesday, June 22nd. The stock was acquired at an average cost of $2.00 per share, for a total transaction of $8,400,000.00. The disclosure for this purchase can be found here.

An institutional investor recently raised its position in BioScrip stock. Diamond Hill Capital Management Inc. raised its stake in shares of BioScrip Inc. (NASDAQ:BIOS) by 2.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,055,476 shares of the company’s stock after buying an additional 74,757 shares during the period. Diamond Hill Capital Management Inc. owned approximately 4.44% of BioScrip worth $5,347,000 at the end of the most recent quarter.

BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.